Entera Bio (ENTX) grants director shares and long-dated stock options
Rhea-AI Filing Summary
Entera Bio Ltd. reported that director Steven D. Rubin received equity compensation consisting of 19,117 ordinary shares granted in lieu of cash director fees for the first two quarters of 2026 and two stock option awards for 33,368 and 43,405 shares at an exercise price of 1.37 per share. The options, expiring on May 7, 2036, were approved after shareholder authorization and a Form S-8 registration and vest over one- and three-year schedules beginning February 1, 2026, with full acceleration upon a Change in Control. Following the share grant, Rubin directly owns 34,117 ordinary shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 19,117 shares
Net Buy
3 txns
Insider
Rubin Steven D
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F2 | 33,368 | $0.00 | $0.00 |
| Grant/Award | Stock Option (right to buy) F3 | 43,405 | $0.00 | $0.00 |
| Grant/Award | Ordinary Shares, par value NIS 0.0000769 per share F1 | 19,117 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 76,773 shares (Direct);
Ordinary Shares, par value NIS 0.0000769 per share — 34,117 shares (Direct)
Footnotes (3)
- F1. The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026.
- F2. Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on February 1, 2026, with one third of the options vesting on February 1, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")).
- F3. Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest on a quarterly basis over a one-year period that began on February 1, 2026, subject to full acceleration upon a Change in Control (as defined in the Plan).
Key Figures
Shares granted in lieu of cash fees: 19,117 ordinary shares
Option grant (3-year vesting): 33,368 options
Option grant (1-year vesting): 43,405 options
+2 more
5 metrics
Shares granted in lieu of cash fees
19,117 ordinary shares
Director fees for first and second quarters of 2026
Option grant (3-year vesting)
33,368 options
Exercise price 1.37 per share; expires May 7, 2036; vests over three years from February 1, 2026
Option grant (1-year vesting)
43,405 options
Exercise price 1.37 per share; expires May 7, 2036; vests quarterly over one year from February 1, 2026
Option exercise price
1.37 per share
Exercise price for both option grants reported on August 7, 2026
Shares owned after grant
34,117 ordinary shares
Direct non-derivative holdings following the 19,117-share equity award
Key Terms
Registration Statement on Form S-8, Change in Control, 2018 Equity Incentive Plan
3 terms
Registration Statement on Form S-8 regulatory
"subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares"
A registration statement on Form S-8 is the U.S. Securities and Exchange Commission filing companies use to register shares they intend to grant to employees, directors, consultants or benefit plans under stock compensation programs. It matters to investors because it signals potential issuance of new shares tied to pay and incentives, which can increase the total shares outstanding — like adding more slices to a pie — reducing each existing share’s ownership and potentially affecting earnings per share and stock value.
Change in Control financial
"subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan)"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
2018 Equity Incentive Plan financial
"as defined in the Company's 2018 Equity Incentive Plan (the "Plan")"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What new equity awards did Entera Bio (ENTX) director Steven D. Rubin receive?
Director Steven D. Rubin received 19,117 ordinary shares and two stock option grants covering 33,368 and 43,405 ordinary shares. The share grant replaced cash fees for serving as a director for the first and second quarters of 2026.
How many Entera Bio (ENTX) stock options were granted to Steven D. Rubin and at what price?
Rubin was granted stock options on 33,368 and 43,405 ordinary shares, each with an exercise price of 1.37 per share. Both option series are scheduled to expire on May 7, 2036, subject to the stated vesting conditions.
What are the vesting schedules of Steven D. Rubin’s ENTX option grants?
One option grant of 33,368 shares vests over three years, with one-third vesting on February 1, 2027 and the rest quarterly over two years. The 43,405-share grant vests quarterly over a one-year period beginning February 1, 2026.
What conditions and approvals applied to Steven D. Rubin’s Entera Bio equity awards?
The option grants were approved by the Board on May 7, 2026, subject to shareholder approval obtained on July 14, 2026 and effectiveness of a Form S-8 registration on August 7, 2026. Vesting accelerates fully upon a defined Change in Control under the equity plan.